Company news

Atea Pharmaceuticals, Inc. news in 2026

Atea Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Atea Pharmaceuticals to Host Third Quarter 2026 Financial Results and Business Update Conference Call on November 9, 2026

November 2, 2026

Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

September 8, 2026

Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

August 12, 2026

Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026

August 5, 2026

Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus

July 27, 2026

Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus

July 14, 2026

Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

June 24, 2026

Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026

May 26, 2026

Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline

May 13, 2026

Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026

Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026

May 5, 2026

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 4, 2026

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026

February 26, 2026

Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026

February 24, 2026

Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

January 8, 2026

Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 6, 2026

Calls in 2026

Decks in 2026